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The	 symptoms	 of	 chronic	 urticaria,	 be	 it	 chronic	 spontaneous	 urticaria	 (CSU)	 or	











the	mechanisms	 and	 assessments	 of	 potential	 cardiotoxicity	 of	 H1	 antihistamines	
when	updosed	to	four	times	their	 licensed	dose.	In	particular,	we	have	focused	on	
the	 potential	 of	 H1	 antihistamines	 to	 block	 hERG	 (human	 Ether‐a‐go‐go‐Related	
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1  | INTRODUC TION
The	 symptoms	 of	 chronic	 urticaria,	 be	 it	 chronic	 spontaneous	 ur‐
ticaria	 (CSU)	 or	 chronic	 inducible	 urticaria	 (CindU),	 are	 mediated	




6	weeks,1	 is	 substantial	 for	 patients,	 their	 family	 and	 friends,	 the	
healthcare	system	and	society.	Continuous	treatment	with	second‐
generation	H1	 antihistamines	 (sgAHs)	 is	 of	 eminent	 importance	 in	
the	 treatment	 of	 patients	 with	 CSU.	 However,	 many	 patients	 are	
poorly	responsive	to	licensed	doses	of	antihistamines.	In	these	pa‐
tients,	 the	current	EAACI	/	GA2LEN/EDF/WAO	guideline	 for	urti‐
caria	 suggests	 updosing	 of	 sgAHs	 up	 to	 fourfold.1	However,	 such	
updosing	 is	 off‐label,	 and	 consequently,	 the	 responsibility	 resides	













the	 cardiac	 safety	 profiles	 of	 9	 sgAHs	 used	 in	 the	 treatment	 of	
chronic	urticaria.	We	hope	that	this	will	eliminate	the	nagging	doubt	
about	the	potential	of	cardiotoxicity	with	updosing	with	an	H1 an‐
tihistamine	 in	 the	 treatment	of	patients	with	chronic	spontaneous	
urticaria.
2  | MECHANISMS AND A SSESSMENTS OF 




nels	 contribute	 to	 cardiac	 repolarization	 by	 carrying	 the	 IKr cur‐




















ers	 highlighted	 that	 the	 CSI	 for	 the	 cardiotoxic	 sgAHs	 terfena‐
dine	 and	 astemizole,	 calculated	 as	 the	 ratio	 between	 hERG	 IC50 
and	the	effective	drug	therapeutic	plasma	concentration	 (ETPC),	
was	 <	 30,	while	 >	 30	 values	 are	 reported	 for	 safer	 sgAHs	 such	
as	cetirizine,	loratadine,	mizolastine,	ebastine	and	fexofenadine.15 
Values	of	CSI	>	30	times	the	threshold	are	a	strong	argument	 in	
support	 of	 the	 cardiovascular	 safety	 of	 antihistamine	 updosing	
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considering	 that	all	drugs	belonging	 to	 this	class	have	 linear	and	
largely	predictable	pharmacokinetics	and	that	plasma	concentra‐
tions	 are	 roughly	 expected	 to	 increase	 proportionally	when	 the	
drug	is	updosed.	Most	sgAHs	are	tightly	bound	to	plasma	proteins	
and	 display	 rather	 low	 distribution	 volumes.16	 Therefore,	 given	
that	only	the	free	drug	fraction	is	available	to	interact	with	hERG	
channels	 and	 that,	 in	 most	 cases,	 therapeutic	 drug	 monitoring	
does	not	discriminate	between	free	and	bound	fractions,	it	seems	










electrolyte	 unbalances	 such	 as	 hypokalemia	 or	 hypomagnesemia,	
previous	cardiac	dysfunction	and	congenital	long	QT	syndrome.










ough	 QT	 (TQT)	 study,	 which	 represents	 the	 reference	 protocol	
for	 drug	 proarrhythmic	 risk	 assessment	 for	 regulatory	 purposes	
using	 a	12‐lead	ECG	 recording.18	 Briefly,	 in	 a	 typical	 TQT	 study,	
the	QT	interval	 is	corrected	for	heart	rate	with	specific	formulas	
such	 as	 the	 Fridericia's	 correction;	 moreover,	 a	 positive	 control	
represented	by	a	drug	unequivocally	proven	to	prolong	QTc	is	al‐
ways	 included,	 and	 candidate	drugs	 are	 investigated	not	 only	 at	
the	recommended	therapeutic	dose	but	also	at	higher	doses	(usu‐








3  | C ARDIAC SAFET Y OF SGAHS USED AT 
HIGHER THAN STANDARD DOSES
The	next	paragraphs	summarize	relevant	preclinical	(hERG	blockade)	





lastine	 is	 20	mg/day.23,24	 This	 drug	 has	 optimal	 pharmacological	
properties	for	updosing	 including	a	high	selectivity	for	H1	 recep‐
tors,	 the	 lack	 of	 a	 significant	 CYP450‐mediated	metabolism	 and	
the	predicted	poor	 retention	 in	 the	brain	being	a	good	substrate	







fold	 higher	 than	 those	 recommended.20,22	 The	 clinical	 evidence	













Both	 cetirizine	 and	 levocetirizine	 have	 been	 successfully	 and	
safely	updosed	for	 the	treatment	of	cholinergic	and	chronic	spon‐
taneous	 urticaria.35‐43	 Both	 drugs	 appear	 remarkably	 safe	 from	 a	
cardiovascular	 point	 of	 view,	 and	 they	 are	 well	 suited	 for	 updos‐
ing.	Cetirizine	is	inactive	on	hERG	channels	in	concentrations	up	to	
3000	 nM	 in	mammalian	 cells.44,45	 This	 is	 higher	 than	 the	Cmax	 at‐
tained	after	a	single	or	repeated	administration	at	doses	up	to	three‐
fold	 higher	 than	 the	 recommended	 one30,46	 (Table	 1).	 Concerning	
levocetirizine,	no	effect	on	cloned	hERG	channels	was	observed	in	
Xenopus	oocytes	at	concentrations	up	 to	30	000	nM.47	This	drug	
reaches	 peak	 plasma	 concentrations	 of	 <1000	 nM	 after	 single	 or	
repeated	administrations	of	the	recommended	5	mg	dose,	whereas	
few	 data	 are	 available	 on	 the	 higher	 doses	 (Table	 1).	 Remarkably,	
however,	a	Cmax	value	of	about	3000	nM	was	recorded	in	volunteers	











ally	 related	 to	 terfenadine	whose	 recommended	 dose	 is	 10	mg/
day.	 After	 being	 absorbed,	 ebastine	 is	 almost	 completely	 con‐
verted	 by	 CYP2J2	 in	 the	 liver	 into	 the	 active	 metabolite	 care‐
bastine.49	 It	 is	carebastine	that	 is	usually	measured	in	plasma	for	
pharmacokinetic	studies.50	In	Xenopus	oocytes,	ebastine	blocked	
heterologously	 expressed	 hERG	 channels	 with	 a	 similar	 affin‐
ity	 (Kd	=	300	vs	400	nM)	but	with	 lesser	efficacy	 (46%	vs	80%)	
than	 terfenadine.51	 No	 data	 are	 available	 on	 the	 effect	 of	 the	
active	 metabolite	 carebastine	 on	 recombinant	 hERG,	 but	 Moss	




















dose (nM) Cmax Updosing (nM)




47107 9333 Single	dose 55046 Threefold:	174046
Repeated	doses 79946 Threefold:	214046






















3113 91‐9234 Single	dose 58621 Sixfold:	334821
Repeated	doses 79234 na
LORATADINE 10100045 138107 97‐9975 Single	dose 5.575 Fourfoldd:	68.375
515074 12.3d 75
Repeated	doses 12.181 na
MIZOLASTINE 35088 22107 98.4114 Single	dose 52789 Fourfold:	226889
Repeated	doses 53989 Fourfold:	244689
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3.4 | Fexofenadine
Fexofenadine	 is	 the	 active	 carboxylated	 metabolite	 of	 terfena‐
dine	 that	 is	 generated	 in	 vivo	by	CYP3A4‐dependent	oxidative	N‐





















Loratadine	 is	 a	 second‐generation	 piperidine	 antihistamine	 drug	
structurally	 related	to	azatadine	and	cyproheptadine.61	Loratadine	
is	 very	well	 tolerated	 because	 it	 lacks	 anticholinergic	 activity	 and	
does	 not	 cross	 the	 blood‐brain	 barrier	 to	 cause	 sedation.62	 After	
oral	 administration,	 this	 drug	 undergoes	 extensive	 first	 pass	 me‐
tabolism	being	converted	by	CYP3A4	and	CYP2D6	to	its	active	me‐
tabolite	 descarboethoxyloratadine	 (desloratadine),	 which	 is	 about	























these	 data	 point	 to	 remarkable	 cardiovascular	 safety	 of	 both	 lo‐
ratadine	 and	desloratadine	even	when	updosed	as	 also	 confirmed	






at	 the	 recommended	5	mg	daily	dose84	 or	 at	 the	dose	of	7.5	mg/


















two	non‐TQT	studies.	 In	 the	 first	of	 these	studies,	Chaufour	et	al.89 
measured	 the	effect	on	QTc	of	10,	20	and	40	mg	mizolastine	given	
as	 single	or	 repeated	daily	doses	 for	7	days,	without	any	 significant	









ommended	 dosage	 of	 rupatadine	 is	 10	mg	 once	 a	 day.	 Studies	 in	
vitro	showed	that	rupatadine	blocks	hERG	channels	with	a	 IC50	of	
8100 nM.94	As	previously	reported	also,	the	hERG	IC50	of	deslorat‐
adine,	 the	major	metabolite	 generated	by	 rupatadine	 in	 vivo,	 is	 in	
the	μM	range.	After	oral	administration	of	single	or	of	repeated	(five	
days)	standard	10	mg	dose	doses,	rupatadine	Cmax	was	always	about	
2000‐fold	 lower	 than	 the	 aforementioned	 average	 IC50	 for	 hERG	
blockade	(Table	1).95,96	Church	and	colleagues2	showed	that	after	a	
single	dose	of	40	mg	(fourfold	higher	than	the	recommended	dose),	



























one	study	has	 shown	 that	 the	use	of	a	combination	of	H1	 antihis‐

























according	 to	WHO	definitions,	people	older	 than	65	years103)	 and	
patients	with	cardiovascular	diseases,	who	require	special	attention.	
These	patients	should	be	warned	not	to	overdose	their	prescribed	
antihistamines	 and	 not	 to	 combine	 them	with	 drugs	 such	 as	 anti‐
fungal	drugs	and	macrolides,	or	food	and	beverages,	such	as	grape‐
fruit	 juice,	 that	 inhibit	 their	 metabolism	 by	 CYPs	 (mainly	 but	 not	
exclusively	CYP3A4),	nor	with	any	drugs	that	prolong	QT	intervals,	
such	 as	 anti‐arrhythmics,	 antimicrobials,	 tricyclic	 antidepressants,	
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